I developed a standard procedure for assessing sensitivity, intra-assay precision, parallelism of sample dilutions, and assay drift, using a single trial assay kit. I used this to compare the performance of 10 commercial kits with an inhouse radloimmunoassay for human thyrotropin. No one kit stood out as clearly superior overall. Differences in calibration between kits were evident in a comparison of thyrotropin concentrations measured in clinical samples, and by direct comparisonof standards from different kits in a single assay. However, all kits gave clinically consistent results with respectto their published normal reference interval. Moreover, the performance of human thyrotropin assay kits has improved during the 14 months of this study.
ences between these methods are summarized in Table 1 . I used the first five to develop the one-kit procedure described here.
Serum samples. I used the kits to assay serum samples that had been stored at -17 #{176}C for as long as three months before assay. The samples were from thyrotoxic and euthyroid subjects who had been characterized by standard thyroid-function tests, including measurement of TSH with the existing in-house RIA (3).
Methods. I prepared extra standards by diluting standards provided in the kit with the zero standard for that kit. The concentrations of the standards were 0.1 milli-int.
unit/L and at least two other concentrations <1 milli-int.
unitlL, the actual values depending on the amount of extra zero standard available. Concentrations >10 milli-int. unitsfL were not used. Three sera with TSH concentrations of approximately 2 milli-int. units/L were diluted serially down to 16-fold with our in-house zero standard (a pool of sera with undetectable TSH by our in-house RIA). Another serum pool ("zero pool") with undetectable TSH was assayed 10 times with each assay to check precision in the thyrotoxic range. I also assayed 10 individual sera (zero TSH) to check for the presence of tracer binding that would produce results lower than the zero standard (nominal TSH <0). Any count more than 2 SD below that of the zero standard was regarded as significantly low. To assess assay drift I assayed three pooled control sera at the beginning and end of each analytical run, using the full kit in a single run to maximize the chance of detecting this drift. For most kits this was 100 to 110 tubes per assay, but with the Serono kit only 60 tubes per assay could be used on a single magnetic separating rack. Serum samples with low or normal TSH as measured by RIA, as well as all serum pools and dilutions, were prepared in advance and stored at -17 #{176}C in individual aliquots for each assay. All specimens and standards were assayed in duplicate. Because several kits recommended an overnight incubation for optimum sensitivity, I used this longer time for eight of the kits. I first tested the Abbott and Amerwell kits using a short incubation time, but repeated some of the studies with overnight incubation when significant assay driftoccurred.Counting time was 10 minutes for all IRMA 
methods.
Eight of the 10 kits were tested in two series, with identical samples within each series, but different samples between the two. The first series included the Hybritech, Henning, Pharmacia, Farmos, and Serono kits. 
<0.2 milli-int. unitIL (Table 2). Nonspecific binding ranged
Responses of the zero standard (nonspecific binding) were from 0.03% to 1.5% of the total counts (Table 3 ). In all Results for assay "drift" are shown in Table 2 . The results for the Bio-Rad kit were equivocal, the individual increments being +2.9%, + 11.8%, and + 18.3%. Of the other methods, only the Abbott and Amersham kits showed significant drift, regardless of whether a long or short incubation was used. When the incubation time for the Abbott kit was increased the drift was decreased but not abolished. Overnight incubation of the Amersham kit reversed the direction of drift. Table 3 lists the expected and observed counts for the zero standard (nonspecific binding), expressed as a percentage of the 1 milli-int. unitlL standard. If a kit did not include a 1 milli-int.
unit/L standard I interpolated the "expected" counts from a straight line joining the two adjacent standards. For the Pharmacia kit, which does not use a zero standard, I extrapolated the zero counts from the counts for the 1.0 and 0.1 milli-int. unitfL standard.
I classified serum TSH concentrations from all kits as "thyrotoxic" or "euthyroid" by reference to the published normal range for each. Results from the in-house RIA were similarly classified, and the classifications for each kit compared with RIA (Table 4) . For all kits, clinical classifications were in close agreement with those by RIA. Where discrepancies occurred, results were borderline in both assays for all but one serum. The number of clinical samples measured in more than one kit was insufficient for me to make a similar inter-kit comparison.
DiscussIon
Kit testing was confined to the range of TSH concentrations covered by the in-house RIA, because I was not planning to use them at higher concentrations. My aim was to find a rapid TSH method with precision and detection limit better than our existing RIA. My financial resources were limited, so I had to develop a testing procedure that balanced information gained against cost. The approach I finally adopted was evolved with the first five kits I tried, and I regard it as a preliminary survey to select just one or two kits for more detailed testing. I omitted inter-assay precision, because extra kits would be needed, and analytical recovery studies, because I was comparing results with an existing method for which such studies had been done (3). These, and cross-reactivity studies, would be performed only on selectedmethods.In retrospect,I think one of the serum dilution series should have been replaced by a recovery experiment.
Several kits recommend overnight incubation for optimal precision and sensitivity. I confirmed this with the Hybritech and Henning kits, so made it standard practice for all kits except Abbott's, because modifications to the data-reduction package would have been required, and Amerwell, because I found little increase in the slope of the standard curve at the longer time. Because of drift in these two methods, I later retested them with overnight incubation.
The longer incubation did not eliminate the problem, but it reversed the direction of drift in the Arnerwell kit, and lowered the detection limit for the Abbott kit (Table 2) . I wanted to compare kits under "ideal" conditions, so I used a 10-mm counting time to minimize counting error. Other modifications have been shown to improve the performance of some kits (17, 18), but in this preliminary assessment they were not tried.
The detection limit data are summarized in Table 2 Comparison of the standard curves I achieved with those presented in the instruction manual as "typical" indicates that a careful examination of such data may provide a good basis for making an initial assessment of likely performance of these kits before any testing is carried out. Serono does not give any typical assay data. Of the other kits, Abbott, Hybritech, Henning, Farmos, and Pharmacia performed as expected. Observed results for nonspecific binding were lower than expected for Amersham and CIS, and higher for DPC and Bio-Rad. In all cases where sensitivity was defined as +2 SD above zero, my experimental detection limits were slightly lower than those quoted in the manual. Serono, Pharmacia, CIS, and DPC did not define their sensitivity. My detection limit was lower than quoted by Serono and higher than quoted by Pharmacia, CIS, and DPC.
The procedure outlined here gave no indication of interassay precision or recovery, but in other respects proved useful in making a preliminary assessment of the relative merits of several kit methods. Data on precision at TSH concentrations at or below the lower limit of normal was quoted by only two kits, Bio-Rad and Farmos, so the information from the precision proffles was particularly useful, even though the number of individual data points obtainable from a single kit is less than ideal. With this information, further tests could be made only on those kits that came closest to the desired performance standards.
In general, those kits that we were offered most recently performed best. It has been suggested by Woodhead and Weeks (20) that we are approaching the limits of precision, sensitivity, and speed achievable with use of radioactively labeled antibodies. Improvements in most recent mrs kits are related to the solid-phase support and handling techniques. Since our tests were completed we have learned (verbal communications) that both Hybritech and Serono have produced improved versions of their IRMA TSH kits.
In conclusion, it would seem that, if our sample is typical, most new TSH kits appearing on the market are effective in distinguishing thyrotoxic from normal subjects. Within the thyrotoxic range, there are differences in sensitivity and precision but it appears that, at present, decisions on which TSH kit to use will be made on the basis ofcost, availability ofback-up services, ease ofhandling, and compatibility with existing laboratory equipment. In our case, the Abbott kit was rejected, partly because it required equipment not already in the laboratory, whereas gamma-counting facilities were immediately available. The final choice between the best performers of the first six tested, Farmos and Henning, was based largely on the simpler handling of the Farmos kit. The last four kits tested were not available at the time this choice was made. Possible relationships have been proposed between the concentrations of selenium in plasma and the incidence of certain diseases, e.g., arteriosclerosis (1,2) and cancer (3,4) . Low Se concentrations may be a risk factor, whereas high concentrations may be somewhat protective against these conditions. So far, only case-control studies have been carried out to support this hypothesis, the most reliable being those conducted on frozen materials, stored for use in cohort studies. In fact, the lack of accurate, simple, quick, and inexpensive analytical methods for determination of Se in plasma has hindered the development of appropriate longitudinal epidemiological studies, with immediate measurements of Se in fresh samples.
At present, Zeeman atomic absorption spectrometry (AAS), with the L'vov platform and matrix modifiers, has been proposed as the analytical technique of choice for determining Se (5) (6) (7) (8) furthermore, most authors found it necessary to use the time-consuming analyte-additiontechnique to control matrix interferences in the analysis of serum samples. On the other hand, our attempt to obtain adequate calibration with acidic aqueous solutions, as described by Welz et al. (6) ,
Here we describe a reliable procedure for determining serum Se after simple dilution. We use Zeeman AAS with a L'vov platform; Cu, Ag, and Mg as matrix modifiers;and a charring step in flowing 02 gas.
The matrix-matched calibrationstandards are prepared in an aqueous solution containing 70 g of bovine serum albumin (BSA) and 9 g of NaC1 per liter.
Materials and Methods

Instrumentation.
For atomic absorption measurements we used a Model 5000 atomic absorption spectrophotometer with Zeeman background corrector, a Model 500 graphite furnace, an AS-40 autosampler, a Model 3600 data station, and an electrodeless discharge lamp for Se (all from PerkinElmer Corp., Norwalk, CT 06856). Dilutions were made with a computerized automatic pipetting system (PD 100; Crony Instruments s.r.l., Rome, Italy). Pyrocoated graphite tubes and pyrolitic graphite L'vov platforms were from Perkin-Elnier.
Reagents. We used doubly distified water for all reagents and standard solutions. Working standard solutions were prepared from a stock 1 g/L standard solution of selenious acid (BDH Chemicals Ltd., Poole, U.K.). Bovine serum albumin (Cohn Fraction V; SorinBiomedica,Verceffi, Italy) and NaC1 (99.999% "Gold Label";Aldrich-Chemie,Steinheim, F.R.G.) were used for the preparation of the standards. Matrix modifiers were Cu(N03)2 .3 H20 (99.5% "AnalaR"; BDH Chemicals Ltd.), AgNO3 ("AnalytiCals"; Carlo Erba, Milano, Italy), Mg(N03)2 6 H20 and HNO3, 65% (both "Suprapur"; Merck, Darmstadt, F.R.G.). We diluted samples and standards with a 2 milL aqueous solution of TritonX-100 (BDH Chemicals Ltd.). Bovine serum Reference Material (RM) 8419, human serum Standard Reference Fresh samples of human serum were collected from subjects belonging to a population sampled from central Italy, enrolled in epidemiological studies.
Procedures.
Matrix-matched calibrating standard solutions were prepared by diluting the 1 g/L Se solution in a
